结构治疗学从分析家那里得到了一个“采购”共识,随着机构投资的增加。 Structure Therapeutics receives a "Buy" consensus from analysts, with rising institutional investments.

结构治疗公司(NASDAQ:GPCR)已经从经纪人那里获得了“Buy”共识,平均12个月的价格目标是81.29美元。 Structure Therapeutics Inc. (NASDAQ:GPCR) has garnered a "Buy" consensus from brokers, with an average 12-month price target of $81.29. 来自JMP证券公司和HC Wainwright等公司的分析师重申了积极的评级,并确定了更高的价格目标。 Analysts from firms like JMP Securities and HC Wainwright have reiterated positive ratings and set higher price targets. 机构投资者也正在增加其在公司中的股权。 Institutional investors are also increasing their stakes in the company. 结构治疗的重点是发展新型口服疗法,治疗2型糖尿病和肥胖症等慢性病。 Structure Therapeutics focuses on developing novel oral treatments for chronic diseases like type-2 diabetes and obesity.